Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Nature medicine - 1 Sept 2018

Kim Seung Tae, Cristescu Razvan, Bass Adam J, Kim Kyoung-Mee, Odegaard Justin I, Kim Kyung, Liu Xiao Qiao, Sher Xinwei, Jung Hun, Lee Mijin, Lee Sujin, Park Se Hoon, Park Joon Oh, Park Young Suk, Lim Ho Yeong, Lee Hyuk, Choi Mingew, Talasaz AmirAli, Kang Peter Soonmo, Cheng Jonathan, Loboda Andrey, Lee Jeeyun, Kang Won Ki

Abstract excerpt

Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifying determinants of response, we performed molecular characterization of tissues and circulating tumor DNA (ctDNA) from 61 patients with mGC who were treated with pembrolizumab as salvage treatment in a prospective phase 2 clinical trial....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Herpesvirus 4, Human

Share to Microsatellite Instability

Share to Neoplasm Metastasis

Share to Patient Selection

Share to Programmed Cell Death 1 Receptor

Share to Stomach Neoplasms

Source

Identifiers

PMID: 30013197
DOI: 10.1038/s41591-018-0101-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.PMID 30013197Read ↗

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric CancerSemantic proximity Read ↗

Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric CancerSemantic proximity Read ↗

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer.Semantic proximity Read ↗

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular featuresSemantic proximity Read ↗

Dynamic phospho-proteogenomic analysis of gastric cancer cells suggests host immunity provides survival benefitSemantic proximity Read ↗

Current treatment and recent progress in gastric cancer.Semantic proximity Read ↗

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.Semantic proximity Read ↗

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancerSemantic proximity Read ↗

Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancerSemantic proximity Read ↗

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapySemantic proximity Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.